1. Volume 72, Issue 1, Pages 10-13 (July 2017)
Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 
Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Johann S. de Bono, Eric J. Small, Neal D. Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Peter De Porre, Mary B. Todd, Margaret K. Yu, Charles J. Ryan 
European Urology 
Volume 72, Issue 1, Pages (July 2017)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
Time to PSA progression on subsequent therapy for the AA-then-AA and AA-then-ENZ subgroups. PSA=prostate-specific antigen; AA=abiraterone acetate+prednisone; ENZ=enzalutamide.
European Urology  , 10-13DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions